Integrative high-throughput studies identify novel targets and drugs for advanced prostate cancer treatment Prostate cancer, a prevalent malignancy ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and dosage goals.

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

Recent health updates highlight the FDA's approval of Lantheus' new prostate cancer imaging agent to enhance production ...

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging ...

When most people think about cancer treatment, they picture chemotherapy, grueling surgeries, harsh drug regimens, and devastating side effects. Medicus ...

There are different ways to manage fatigue during prostate cancer treatment, including exercise, sleep, complementary ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment. A recent ...